This Week: We’re currently working on our Year in Review, which we will begin publishing in segments later this month. In the meantime, our Bulletins will be a little shorter than usual. Disappointing PCN-101 Results See atai Stock Tumble Further MAPS’ Second Phase 3 Trial of MDMA for PTSD is “Successful” New York Bill Would Legalise a Number of Psychedelics Oregon Begins Accepting Applications…

Source

Previous articleGH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
Next articlePharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation